{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:39:24Z","timestamp":1786977564975,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":549,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) elicits a pro-inflammatory state, which is associated with impaired clinical outcomes, but no anti-inflammatory therapies have demonstrated a clinical benefit yet. Inflammatory pathways related with the interleukin-1 axis are overactivated during episodes of acute HF. Colchicine, an anti-inflammatory drug with proven benefits in acute pericarditis and ischaemic heart disease, may target this inflammatory response. This study aims to assess the efficacy of colchicine in acute HF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>COLICA is a multicentre, randomized, double-blind, placebo-controlled trial enrolling 278 patients across 12 sites. Patients presenting with acute HF, clinical evidence of congestion requiring \u226540\u2009mg of intravenous furosemide and N-terminal pro-B-type natriuretic peptide (NT-proBNP) &amp;gt;900\u2009pg\/ml, are eligible for participation. Patients are enrolled irrespective of left ventricular ejection fraction, HF type (new-onset or not) and setting (hospital or outpatient clinic). Patients are randomized 1:1 within the first 24\u2009h of presentation to either placebo or colchicine, with an initial loading dose of 2\u2009mg followed by 0.5\u2009mg every 12\u2009h for 8\u2009weeks (reduced dose if &amp;lt;70\u2009kg, &amp;gt;75\u2009years old, or glomerular filtration rate &amp;lt;50\u2009ml\/min\/1.73\u2009m2). The primary efficacy endpoint is the time-averaged proportional change in NT-proBNP concentrations from baseline to week 8. Key secondary and exploratory outcomes include symptoms, diuretic use, worsening HF episodes, related biomarkers of cardiac stress and inflammation, total and cardiovascular readmissions, mortality and safety events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COLICA will be the first randomized trial testing the efficacy and safety of colchicine for acute HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3300","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T16:53:38Z","timestamp":1717520018000},"page":"1999-2007","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA)"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-9540","authenticated-orcid":false,"given":"Domingo","family":"Pascual-Figal","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, Universidad de Murcia , Murcia ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"N\u00fa\u00f1ez Villota","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Cl\u00ednico Universitario de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, Universidad de Murcia , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Cl\u00ednico Universitario de Santiago , Santiago de Compostela ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Taibo-Urqu\u00eda","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"IIS-Hospital Fundaci\u00f3n Jim\u00e9nez Diaz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Ll\u00e0cer Iborra","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Villar","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Cl\u00ednico Universitario de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxel","family":"Soler","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Germans-Trial i Pujol , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mirabet","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Santa Creu i Sant Pau , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[{"name":"Fondazione Toscana Gabriele Monasterio, Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Riquelme-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, Universidad de Murcia , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anguita S\u00e1nchez","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Universitario Reina Sof\u00eda , Cordoba ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mart\u00ednez-Sell\u00e9s","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Universidad Europea, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Universitario de Salamanca, IBSAL , Salamanca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"IIS-Hospital Fundaci\u00f3n Jim\u00e9nez Diaz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bay\u00e9s-Gen\u00eds","sequence":"additional","affiliation":[{"name":"CIBER cardiovascular , Madrid ,","place":["Spain"]},{"name":"Hospital Germans-Trial i Pujol , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the COLICA Investigators (see Appendix)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"2026010913051639700_ejhf3300-bib-0001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026010913051639700_ejhf3300-bib-0002","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051639700_ejhf3300-bib-0003","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"2026010913051639700_ejhf3300-bib-0004","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"2026010913051639700_ejhf3300-bib-0005","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jchf.2019.04.022","article-title":"CORT-AHF study: Effect on outcomes of systemic corticosteroid therapy during early management acute heart failure","volume":"7","author":"Mir\u00f3","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913051639700_ejhf3300-bib-0006","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1235178","article-title":"Inflammation in acute heart failure","volume":"10","author":"Garofalo","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026010913051639700_ejhf3300-bib-0007","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jacc.2018.11.054","article-title":"The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure","volume":"73","author":"Pascual-Figal","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913051639700_ejhf3300-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026010913051639700_ejhf3300-bib-0009","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026010913051639700_ejhf3300-bib-0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000000378","article-title":"Interleukin-1 blockade in acute decompensated heart failure: A randomized, double-blinded, placebo-controlled pilot study","volume":"67","author":"Van Tassell","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026010913051639700_ejhf3300-bib-0011","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2026010913051639700_ejhf3300-bib-0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: In-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"2026010913051639700_ejhf3300-bib-0013","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913051639700_ejhf3300-bib-0014","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913051639700_ejhf3300-bib-0015","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913051639700_ejhf3300-bib-0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","article-title":"Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study","volume":"2","author":"Deftereos","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026010913051639700_ejhf3300-bib-0017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913051639700_ejhf3300-bib-0018","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","article-title":"The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure","volume":"21","author":"Briasoulis","year":"2016","journal-title":"Heart Fail Rev"},{"key":"2026010913051639700_ejhf3300-bib-0019","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10741-020-09949-5","article-title":"Distinctive patterns of inflammation across the heart failure syndrome","volume":"26","author":"Schiattarella","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026010913051639700_ejhf3300-bib-0020","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"2026010913051639700_ejhf3300-bib-0021","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Van Tassell","year":"2013","journal-title":"Circulation"},{"key":"2026010913051639700_ejhf3300-bib-0022","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"2026010913051639700_ejhf3300-bib-0023","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/CIRCRESAHA.116.308688","article-title":"Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction","volume":"118","author":"Zhao","year":"2016","journal-title":"Circ Res"},{"key":"2026010913051639700_ejhf3300-bib-0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"van Tassell","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026010913051639700_ejhf3300-bib-0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/1756-185X.12632","article-title":"Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging","volume":"19","author":"Kobayashi","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2026010913051639700_ejhf3300-bib-0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2026010913051639700_ejhf3300-bib-0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2459\/JCM.0000000000001079","article-title":"Colchicine for the treatment of cardiovascular diseases: Old drug, new targets","volume":"22","author":"Andreis","year":"2020","journal-title":"J Cardiovasc Med"},{"key":"2026010913051639700_ejhf3300-bib-0028","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","article-title":"A randomized trial of colchicine for acute pericarditis","volume":"369","author":"Imazio","year":"2013","journal-title":"N Engl J Med"},{"key":"2026010913051639700_ejhf3300-bib-0029","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13464","article-title":"Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2026010913051639700_ejhf3300-bib-0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175126","article-title":"Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction","volume":"929","author":"Shen","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"2026010913051639700_ejhf3300-bib-0031","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/clc.23830","article-title":"Association of colchicine use for acute gout with clinical outcomes in acute decompensated heart failure","volume":"45","author":"Roth","year":"2022","journal-title":"Clin Cardiol"},{"key":"2026010913051639700_ejhf3300-bib-0032","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Investig"},{"key":"2026010913051639700_ejhf3300-bib-0033","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2023-002360","article-title":"Colchicine in patients with heart failure and preserved left ventricular ejection fraction: Rationale and design of a prospective, randomised, open-label, crossover clinical trial","volume":"10","author":"Shchendrygina","year":"2023","journal-title":"Open Heart"},{"key":"2026010913051639700_ejhf3300-bib-0034","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/ejhf.3052","article-title":"Personalizing anti-inflammatory therapy in heart failure: A new way","volume":"25","author":"Pascual-Figal","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/1999\/65511350\/eurjhf_26_9_1999.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/1999\/65511350\/eurjhf_26_9_1999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:06:13Z","timestamp":1767981973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/9\/1999\/8328669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,6,4]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3300","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"2024-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}